Esteban Martinez and Steven Grinspoon on non-communicable diseases and the REPRIEVE trial episode artwork

EPISODE · Apr 29, 2026 · 25 MIN

Esteban Martinez and Steven Grinspoon on non-communicable diseases and the REPRIEVE trial

from The Lancet HIV in conversation with · host The Lancet Group

Non-communicable diseases (NCDs) increasingly represent a leading cause of morbidity and mortality among people with HIV. People with HIV are at high risk of developing NCDs, often at younger ages and more severely than people without HIV. Esteban Martinez from the Hospital Clinic and University of Barcelona, and Steven Grinspoon from the Massachusetts General Hospital and Harvard Medical School, join us to explore the importance of NCDs and how data from the REPRIEVE trial can help us understand and prevent the underlying causes increasing the risk of NCDs in people with HIV. Click here to read the full articles: https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00031-7/fulltext https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00354-6/fulltext https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00036-6/fulltext

Episode metadata supplied by the publisher feed · Published Apr 29, 2026

Embed this episode

Ready to play

Esteban Martinez and Steven Grinspoon on non-communicable diseases and the REPRIEVE trial

0:00 25:54

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Lancet HIV in conversation with?

This episode is 25 minutes long.

When was this The Lancet HIV in conversation with episode published?

This episode was published on April 29, 2026.

Can I download this The Lancet HIV in conversation with episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!